Despite a high prevalence of drug and alcohol (AOD)-related morbidity among patients presenting to emergency departments, acute care settings and pre-admission clinics, previous research has found AOD-related morbidity is not commonly identified on admission.
The National Drug and Alcohol Research Centre (NDARC) have been invited to work with 5 remote NSW communities to retrospectively evaluate a suite of interventions aimed at prevention of drug and alcohol harms from 2012-2014.
This project aims to describe patterns of AAS and PIEDs use; where people are sourcing them from and why; users' experience of harms; and users' utilisation of health services.
Opioid agonist treatment is commonly initiated as a first-line treatment for individuals with pharmaceutical opioid dependence, even though much of the evidence base for the use of pharmacotherapy treatments in opioid dependence has been derived from studies conducted with primarily or exclusivel
This project explores the characteristics of methamphetamine users entering treatment in therapeutic communities, and assesses the effectiveness of a specialist amphetamine-type stimulants (ATS) intervention in therapeutic communities.
People who use heroin commonly spend time in prison. Contact with treatment services after release from prison is important for reducing the risk that released heroin users will return to regular drug use.
The traditional response of the human service system to the needs of homeless people experiencing mental health conditions involves specialist homelessness, drug and alcohol, and mental health services providing support in a largely autonomous fashion.
This project involves the development of a resource for the identification, management and, if appropriate, referral of women who are pregnant and have a substance misuse problem.
The Centre of Research Excellence in Mental Health Systems Improvement (CREMSI) was funded in 2012 by the National Health and Medical Research Council and is led by the University of Queensland.
Treatment admissions for cannabis use disorders have risen considerably over the last few years, globally and within Australia. There is currently no effective pharmacotherapy for cannabis dependence, and very low abstinence rates reported from psychotherapy alone.
